### 2015 Towards an HIV Cure Symposium

**18 & 19 July 2015**

**Hyatt Regency Hotel, Vancouver, Canada**

---

#### Saturday 18th July

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>08h30 – 09h00</td>
<td>Registration</td>
</tr>
<tr>
<td>09h00 – 09h20</td>
<td>Opening</td>
</tr>
<tr>
<td>09h20 – 09h50</td>
<td>Keynote</td>
</tr>
<tr>
<td>09h50 – 10h05</td>
<td>Community</td>
</tr>
<tr>
<td>10h05 – 11h25</td>
<td>Session 1</td>
</tr>
</tbody>
</table>

**Opening**

**Welcome and Introduction**

**Keynote**

**Progress and Challenges in HIV Cure Research**

Daniel Kuritzkes, Brigham & Women’s Hospital, Harvard Medical School, United States

**Community**

**Community Involvement in HIV Cure-related Research: Not Just Guinea Pigs**

Matthew Sharp, Long-term Survivor, HIV Education and Advocacy Consultant, United States

Chairs: Françoise Barré-Sinoussi, Inserm and Institut Pasteur, France and Jack Whitescarver, United States

**Session 1**

**Pathways to establishing and maintaining HIV latency**

Chairs: Éric Cohen, Institut de Recherches Cliniques de Montréal, Canada and Michaela Muller-Trutwin, Institut Pasteur, France

**Invited speaker**

**HIV-1 broadly neutralizing antibodies: Potential role in HIV treatment approaches**

John Mascola, Vaccine Research Center, NIAID/NIH, United States

**OA1-1**

**CTLA-4-expressing memory CD4+ T-cells are critical contributors to SIV viral persistence**

Colleen McGary, Emory University, United States

**OA1-2**

**Molecular Determinants of HIV-1 Permissiveness and Persistence in Gut-Homing CD4+ T-Cells Expressing the Th17 Marker CCR6**
10h55 – 11h10  OA1-3  
**Dasatinib preserves SAMHD1 antiviral activity in CD4+ T cells treated with IL-7**

Jose Alcami, Instituto de Salud Carlos III, Spain

11h10 – 11h25  OA1-4 LB  
**Estrogen blocks HIV re-emergence from latency and points to gender-specific differences in HIV reservoirs**

Jonathan Karn, Case Western Reserve University School of Medicine, United States

11h25 – 11h55  Break

11h55 – 13h00  Roundtable  
**Advancing Paediatric HIV Cure Research**

Chair: Jintanat Ananworanich, US Military HIV Research Program

Panelists:
Marie Elizabeth Theunissen, FAMCRU, South Africa
Hugo Soudeyns, CHU Sainte-Justine Research Center and Université de Montréal, Canada
Deborah Persaud, Johns Hopkins University, United States
Ann Chahroudi, Emory University School of Medicine, United States
Daria Hazuda, Merck, United States

13h00 – 14h00  Lunch Break

14h00 – 15h50  Session 2  
**Activating latent HIV infection in vitro and in vivo**

Chairs: David Margolis, University of North Carolina, United States and Monique Nijhuis, University Medical Center Utrecht, Netherlands

14h00 – 14h20  Invited speaker  
**Immune recognition following latency reversal**

Marcus Altfeld, Heinrich-Pette-Institute, Leibniz Institute for Experimental Virology Hamburg, Germany

14h20 – 14h35  OA2-1  
**Histone deacetylase inhibitors alter the accumulation of spliced HIV mRNA - implications for virus production**

Talia Mota, Doherty Institute, The University of Melbourne, Australia
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Presenter(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>14h35 – 14h50</td>
<td>OA2-2</td>
<td>Latency reversal Agent (LRA) Romidepsin Reactivates Latent Virus in Two Rhesus Macaque (RM) Models of Controlled SIV Infection in the Absence of Antiretroviral Therapy (ART)</td>
<td>Benjamin Policicchio, University of Pittsburgh, United States</td>
</tr>
<tr>
<td>14h50 – 15h05</td>
<td>OA2-3</td>
<td>Vorinostat, Panobinostat, and Romidepsin Nonselectively Activate Transcription from Quiescent HIV-1 Proviruses in HIV-infected Individuals on Long-term Suppressive Anti-retroviral Therapy</td>
<td>Kirston Barton, University of Sydney, Australia</td>
</tr>
<tr>
<td>15h05 – 15h20</td>
<td>OA2-4</td>
<td>Modulation of HERV family expression after treatment with HDAC inhibitors</td>
<td>Miguel de Mulder Rougvie, George Washington University, United States</td>
</tr>
<tr>
<td>15h20 – 15h35</td>
<td>OA2-5</td>
<td>Ingenol Efficiently Reactivates Latent HIV in cells from aviremic patients</td>
<td>Vicente Planelles, University of Utah, United States</td>
</tr>
<tr>
<td>15h35 – 15h50</td>
<td>OA2-6 LB</td>
<td>CD4 Mimetics Sensitize HIV-1-Infected Cells to ADCC</td>
<td>Andres Finzi, The CHUM Research Center, University of Montreal &amp; McGill University, Canada</td>
</tr>
<tr>
<td>15h50 – 17h00</td>
<td>Roundtable</td>
<td>Combination Therapy Trials</td>
<td>Chair: Daniel Kuritzkes, Brigham &amp; Women’s Hospital, Harvard Medical School</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Panelists:</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Brigitte Autran, Hôpital Pitié Salpêtrière, CIMIT-Paris, UPMC/INSERM U1135, France</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Joseph Eron, University of North Carolina, United States</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Irina Tcherepanova, Argos Therapeutics, Inc., United States</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Jeffrey Lifson, Frederick National Laboratory for Cancer Research, United States</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>David Evans, Project Inform, United States</td>
<td></td>
</tr>
<tr>
<td>17h00 – 18h30</td>
<td>Poster Exhibition &amp; Networking Session</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Session 3: Novel strategies to identify and quantify virus persistence in vivo (biomarkers)

- **09h00 – 10h35**
  - **Invited speaker**
  - **Engineering T cells to functionally cure HIV-1 infection**
    - James Riley, Perelman School of Medicine, University of Pennsylvania, United States
  - **OA3-1**
    - **Immunological Markers associated with HIV Persistence During ART Identified by Iterated Conditional Random Forests Analysis**
    - Remi Fromentin, CRCHUM, Canada
  - **OA3-2**
    - **Patient-derived defective HIV-1 proviruses containing large internal deletions can be transcribed and translated**
    - Ross Pollack, The Johns Hopkins University, United States
  - **OA3-3**
    - **Cell-associated HIV-1 unspliced to multiply spliced RNA ratio at 12 weeks ART correlates with markers of immune activation and apoptosis and predicts the CD4+ T-cell count at 96 weeks ART**
    - Alexander Pasternak, Academic Medical Center of the University of Amsterdam, Netherlands
  - **OA3-4**
    - **Distinct HIV Genetic Populations in Effector Memory T-cells after Prolonged Therapy**
    - Eunok Lee, Westmead Millennium Institute for Medical Research; University of Sydney, Australia
  - **OA3-5 LB**
    - **Investigating the Role of the Immune Checkpoint Receptor TIGIT in T cells during HIV Disease Progression and as a Target for Immune Restoration**
    - Glen Chew, University of Hawaii, United States

### Break

**11h00 – 12h35**

- **Session 4: Immunology and persistence**
Chairs: Di Yu, Monash University, Australia and Sarah Read, NIAID/DAIDS, NIH, United States

11h00 – 11h20 Invited speaker
CHERUB: Collaboration in HIV Eradication in the UK; Predictors of PTC and Viral Reactivation Strategies
Sarah Fidler, Imperial College London, United Kingdom

11h20 – 11h35 OA4-1 Trancriptomics and Metabolomics identify inflammatory profiles that segregate subjects with High and Low inducible HIV reservoir
Rafick-Pierre Sekaly, Case Western Reserve University, United States

11h35 – 11h50 OA4-2 Virologic and immunologic correlates of viral control post-ART interruption in SIV-infected rhesus macaques
Mirko Paiardini, Emory University, United States

11h50 – 12h05 OA4-3 Zinc Finger Nuclease Gene Editing for Functional Cure in a Nonhuman Primate Model of HIV/AIDS
Christopher Peterson, Fred Hutchinson Cancer Research Center, United States

12h05 – 12h20 OA4-4 LB HIV-1 virological remission for more than 11 years after interruption of early initiated antiretroviral therapy in a perinatally-infected child
Asier Saez-Cirion, Institut Pasteur, France

12h20 – 12h35 OA4-5 LB A Novel Therapeutic HIV-1 Vaccine Trial in Patients under HAART
Frank Tung, GeneCure Biotechnologies, United States

12h35-14h00 Lunch Break

14h00 – 15h00 Roundtable Key Partnerships: Community & Private Sector
Chair: Sharon Lewin, Doherty Institute, The University of Melbourne

Panelists:
David Margolis, University of North Carolina at Chapel Hill, United States
Andrew Spaltenstein, GlaxoSmithKline, United States
Lynda Dee, CARE CAB; AIDS Action Baltimore, United States
Erik Iverson, Infectious Diseases Research Institute, United States
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 15h00 – 15h30 | **Closing Lecture**  
HBV Cure: Possible Lessons for HIV-AIDS  
Stephen Locarnini, Victorian Infectious Diseases Reference Laboratory, Doherty Institute, Australia  
Chair: Steven Deeks, University of California, San Francisco, United States |
| 15h30 – 15h45 | IAS-ANRS HIV Cure Young Investigator Prize Ceremony  
Chairs: Chris Beyrer, Johns Hopkins Bloomberg School of Public Health, United States and Jean-François Delfraissy, ANRS, France |
| 15h45 – 16h00 | Closing Remarks  
Françoise Barré-Sinoussi, Institut Pasteur & Inserm, France  
Carl Dieffenbach, NIAID/NIH, United States |